Literature DB >> 10477735

Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

T Holyoake1, X Jiang, C Eaves, A Eaves.   

Abstract

Chronic myeloid leukemia (CML) is characterized by an increased proliferative activity of the leukemic progenitors that produce an elevated number of mature granulocytes. Nevertheless, cell cycle-active agents, even in very high doses, are alone unable to eradicate the leukemic clone, suggesting the presence of a rare subset of quiescent leukemic stem cells. To isolate such cells, we first used Hoechst 33342 and Pyronin Y staining to obtain viable G(0) and G(1)/S/G(2)/M fractions of CD34(+) cells by fluorescence-activated cell sorting (FACS) from 6 chronic-phase CML patients' samples and confirmed the quiescent and cycling status of the 2 fractions by demonstration of expected patterns of Ki-67 and D cyclin expression. Leukemic (Ph(+)/BCR-ABL(+)) cells with in vitro progenitor activity and capable of engrafting immunodeficient mice were identified in the directly isolated G(0) cells. Single-cell reverse transcriptase-polymerase chain reaction (RT-PCR) analysis showed that many leukemic CD34(+) G(0) cells also expressed BCR-ABL mRNA. CD34(+) from 8 CML patients were also labeled with carboxyfluorescein diacetate succinimidyl diester (CFSE) before being cultured (with and without added growth factors) to allow viable cells that had remained quiescent (ie, CFSE(+)) after 4 days to be retrieved by FACS. Leukemic progenitors were again detected in all quiescent populations isolated by this second strategy, including those exposed to a combination of flt3-ligand, Steel factor, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor. These findings provide the first direct and definitive evidence of a deeply but reversibly quiescent subpopulation of leukemic cells in patients with CML with both in vitro and in vivo stem cell properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477735

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  149 in total

Review 1.  Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

2.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

Review 3.  [Tumor stem cell research - basis and challenge for diagnosis and therapy].

Authors:  Heidrun Karlic; Harald Herrmann; Axel Schulenburg; Thomas W Grunt; Sylvia Laffer; Irina Mirkina; Rainer Hubmann; Medhat Shehata; Brigitte Marian; Edgar Selzer; Michael Pfeilstöcker; Elisabeth Pittermann; Ulrich Jäger; Hubert Pehamberger; Christoph Zielinski; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2010-07-22       Impact factor: 1.704

4.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

5.  Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.

Authors:  Yanzhi Du; Yuan Xia; Xiaoling Pan; Zi Chen; Aihua Wang; Kankan Wang; Junmin Li; Ji Zhang
Journal:  Antioxid Redox Signal       Date:  2013-10-24       Impact factor: 8.401

6.  IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.

Authors:  Kai Zhao; Ling-Ling Yin; Dong-Mei Zhao; Bin Pan; Wei Chen; Jiang Cao; Hai Cheng; Zhen-Yu Li; De-Peng Li; Wei Sang; Ling-Yu Zeng; Kai-Lin Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

7.  Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.

Authors:  Annelie E Abrahamsson; Ifat Geron; Jason Gotlib; Kim-Hien T Dao; Charlene F Barroga; Isabel G Newton; Francis J Giles; Jeffrey Durocher; Remi S Creusot; Mobin Karimi; Carol Jones; James L Zehnder; Armand Keating; Robert S Negrin; Irving L Weissman; Catriona H M Jamieson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 8.  Modeling Tumor Clonal Evolution for Drug Combinations Design.

Authors:  Boyang Zhao; Michael T Hemann; Douglas A Lauffenburger
Journal:  Trends Cancer       Date:  2016-03

Review 9.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

10.  P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells.

Authors:  Byeong-Chel Lee; Tao Cheng; Gregor B Adams; Eyal C Attar; Nobuyuki Miura; Sean Bong Lee; Yoriko Saito; Ivona Olszak; David Dombkowski; Douglas P Olson; Julie Hancock; Peter S Choi; Daniel A Haber; Andrew D Luster; David T Scadden
Journal:  Genes Dev       Date:  2003-07-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.